EUROPEAN FORUM OF PHARMACEUTICAL ASSOCIATIONS AND THE WORLD HEALTH ORGANIZATION

Report on the Eighth Annual Meeting

Lisbon, Portugal
12–13 November 1999
EUROPEAN HEALTH21 TARGET 8
REDUCING NONCOMMUNICABLE DISEASES
By the year 2020, morbidity, disability and premature mortality due to major chronic diseases should be reduced to the lowest feasible levels throughout the Region

EUROPEAN HEALTH21 TARGET 16
MANAGING FOR QUALITY OF CARE
By the year 2010, Member States should ensure that the management of the health sector, from population-based health programmes to individual patient care at the clinical level, is oriented towards health outcomes

EUROPEAN HEALTH21 TARGET 20
MOBILIZING PARTNERS FOR HEALTH
By the year 2005, implementation of policies for health for all should engage individuals, groups and organizations throughout the public and private sectors, and civil society, in alliances and partnerships for health

(Adopted by the WHO Regional Committee for Europe at its forty-eighth session, Copenhagen, September 1998)

ABSTRACT

EuroPharm Forum was founded in 1992. This is the Report of the Eighth Annual Meeting, which took place in Lisbon in November 1999. Sixty-four participants from 29 countries participated in the meeting which consisted of a business and professional session, including status reports of activities during the past year, together with proposals for future activities and a poster exhibition. The meeting was linked to the 3rd International Symposium on the role of the pharmacist in health promotion and disease prevention: ‘Pharmacy services: achieving patient’s quality of life’. During the business part of the meeting, applications for membership from pharmaceutical associations in the Russian Federation and the Czech Republic were approved and observer status was granted to the European Association of Faculties of Pharmacy. A new project on Pharmacists and HIV/AIDS was established, as well as a twinning programme. The professional part consisted of five project workshops and a Symposium on Asthma Services in European Pharmacies as an activity within the project on Asthma services, which is directed towards health promotion and better management of patients with asthma.

Keywords
SOCieties, PHARMACEUTICAL PHARMACEUTICAL SERVICES PHARMACISTS HEALTH PROMOTION ASTHMA – prevention and control – drug therapy CONGRESSES EUROPE

© World Health Organization – 2000
All rights in this document are reserved by the WHO Regional Office for Europe. The document may nevertheless be freely reviewed, abstracted, reproduced or translated into any other language (but not for sale or for use in conjunction with commercial purposes) provided that full acknowledgement is given to the source. For the use of the WHO emblem, permission must be sought from the WHO Regional Office. Any translation should include the words: The translator of this document is responsible for the accuracy of the translation. The Regional Office would appreciate receiving three copies of any translation. Any views expressed by named authors are solely the responsibility of those authors.
Introduction

The Eighth Annual Meeting was this year linked to the 3rd International Symposium which was the third symposium to be held on the role of the pharmacist in health promotion and disease prevention, entitled *Pharmacy services: achieving patients’ quality of life*. It was organized by the two national pharmaceutical associations in Portugal, Ordem Dos Farmacêuticos and Associação Nacional Das Farmacias, together with EuroPharm Forum, and held in association with the International Pharmaceutical Federation (FIP) and the Pharmaceutical Group of the European Union (PGEU). It presented recent developments in the different subjects related to the rational use of medicines and pharmaceutical care in practice, focusing pharmacy services towards improving the patient’s quality of life. A manned poster session with 20 different posters on the subject was part of the Symposium and the topical subjects created much interest on the part of the participants.

The Symposium, held over one and a half days on 11 and 12 November, was followed by a half-day meeting comprising the business session of the Eighth Annual Meeting of the EuroPharm Forum. The professional session on 13 November comprised five parallel workshops on the current projects and ended with an overview of the workshops presented to all participants.

Finally, the EuroPharm Forum Symposium on Asthma Services in European Pharmacies took place on 13 November 1999 as an activity within the project on asthma services. The project task force is directed towards health promotion and better management of patients with asthma. Participants were given a professional update, and models to assess the quality of care processes were presented together with various practice situations, how to link the projects and, not least, results of the progress made so far. The project protocol entitled *Pharmacy-based asthma services, protocol and guidelines* is available on request from the EuroPharm Forum Secretariat.

All the events took place at the Associação Nacional Das Farmacias (ANF) in Lisbon, Portugal from 11 to 13 November 1999.

Opening session

The President of EuroPharm Forum, Hans-Günter Friese, opened the Meeting by welcoming the participants on behalf of the Executive Committee, and thanked the Portuguese hosts for making the arrangements for the meeting. He was pleased to note that there were 64 participants from 29 countries and 5 of the observer organizations represented at the meeting.

Mr Friese said he was honoured to welcome Dr Asvall, WHO Regional Director for Europe. He also gave a special welcome to representatives from the Czech Republic and the Russian Federation, whose associations had applied for membership of the Forum. Two of the three former Presidents of EuroPharm Forum were also present, indicating their continued interest in the Forum’s activities. Initiatives had recently been taken to establish a Pharmaceutical Forum of the Americas and the former President, Mr Joep Winters, had played a significant role in facilitating this process. Mr Friese ended by thanking Dr Asvall for fitting this meeting into a very busy schedule in order to address the Forum, and gave him the floor.

In his address to the Forum, Dr Asvall focused on the subjects of depression and family planning and recommended that EuroPharm Forum start to think about projects in these areas.
Business session

Report of the Executive Committee

After the provisional programme (Annex 1) had been approved, the President presented the annual report of the Executive Committee for the period October 1998 to November 1999 (Annex 2), which had been circulated to members. He pointed to the remarkable results made by the Forum during the period and the increased visibility which had been obtained, not least due to the website and the newsletter. There being no comments from members, the report was approved.

Financial report

Profit and loss 1998, including the auditor’s report

The Treasurer, Mr Reijo Purasmaa, listed the membership fees paid in 1999 and presented the profit and loss statement for 1998 (Annex 3). The Forum took note of the report of the Auditor, Mr Wally Dove, who had declared the accounts to be in order. He made the following observations.

- As the accounting method is on a cash basis, i.e. what has been received and paid, rather than on an accruals basis, i.e. on the basis of what should have been received and paid, timing must be taken into account.
- The shortfalls in membership fees could be treated as bank charges or short payments to highlight payment problems.
- Future budgets are sensitive to continuing contributions from WHO. The Forum should, therefore, have a fall-back position.

In reply to the last point, the President mentioned that he would be meeting the new Regional Director soon and hoped that WHO would continue to support the Forum with its contributions. Dr Asvall replied that EuroPharm was included in the budget for the next biennium.

There being no objections, the profit and loss account for 1998 was accepted without comment.

Budget 1999–2000

The Treasurer put forward the budget for 1999–2000 (Annex 4), including the revised budget for 1999 showing actual figures to date as opposed to the original budget. The WHO contribution was not included as the total contribution covered a biennium and was therefore paid in 1998. Similarly, the budget for 2000 included the total expected WHO contribution for the biennium.

Loek Arts (Netherlands) asked if the costs of the new project were included in the budget for 2000. Ida Gustafsen (Professional Secretary) replied that an increase in meetings/travel was included, but the rest of the work would be done either by the task force manager, whose association paid the expenses, or by the Professional Secretary, whose salary was included in the budget. However, if experts were needed or a pilot project was to be launched, further funds would be needed.

Wally Dove (United Kingdom) asked if it was wise to keep the membership fee for 2000 at the same level as 1999, as associations more readily received regular small increases than infrequent large jumps in the fees. The President said that the fees would remain the same for 2000 because this had been agreed at the previous annual meeting, but that they would be re-assessed for the following year.

The budgets were then unanimously accepted.
Application for membership and observer status

Applications for membership had been received from the Russian Pharmaceutical Association and the Czech Chamber of Pharmacists and had been sent out to participants prior to the meeting as background documents. Under the Forum’s statutes, the Executive Committee had already given preliminary consideration to the applications and recommended to the Forum that they be approved. The Forum voted unanimously to accept the recommendation that the Russian Pharmaceutical Association and the Czech Chamber of Pharmacists should be admitted to full membership.

Representatives of both associations gave a short address and were welcomed by the members of the Forum.

The Forum had also received an application for observer status from the European Association of Faculties of Pharmacy (EAFP). The Executive Committee considered that the involvement of the EAFP would help facilitate the achievement of the Declaration on pharmaceutical service and educational needs, approved by the Forum in 1998, and recommended that observer status be granted. The application was put to the Forum and unanimously approved.

On behalf of the President of EAFP, Dick Tromp (EAFP) thanked the Forum and said that approval of observer status was certainly a step towards the implementation of the Forum’s Declaration.

The President told the Meeting that in considering the applications for membership, the Executive Committee had found that certain aspects of the statutes of the Forum were unclear. The Executive Committee had therefore decided that the statutes should be reviewed and would probably be proposing some changes to be tabled at the next annual meeting for approval. He invited members to review them as well and forward comments to the Secretariat.

Latest progress and future plans of the projects

The President informed the participants about the five parallel workshops to be held the following morning and encouraged them to attend.

At the request of the President, Ida Gustafsen then introduced a new method of project planning and reporting which would allow for better coordination of the tasks and more realistic planning. The elements of a standard project had been identified and separated into three phases: preliminary, developmental and implementation/follow-up (Annex 5). These had been plotted in a circle to illustrate that each project was an ongoing process since it would go through most of the elements more than once when it was being adjusted and the protocol revised in accordance with the evaluation. The idea was to plot in each project on the circle in order to make a plan for the future, showing future activities listed on a planning line. By comparing the five planning lines and making any necessary adjustments, it would be possible to fit all the projects together in a realistic plan.

The task force managers reported on the latest achievements within each project and outlined future activities. The reports are attached as under:

- Ask about your medicines (QaM) – André Masy (Annex 6)
- Asthma services – Dick Tromp (Annex 7)
- CINDI (Hypertension management) – Suzete Costa (Annex 8)
- Diabetes care – Maria Augusta Soares (Annex 9)
- Smoking cessation – Ida Gustafsen on behalf of Eeva Teräsvirta (Annex 10).
The Pharmacy-based asthma services, protocol and guidelines was presented as an official WHO publication.

On behalf of all the task force managers, Dick Tromp encouraged the members of the Forum to appoint active and practising pharmacists as task force members – and to support them – in order to facilitate the implementation of the projects.

Dr Asvall told the Forum that in June 2001 there would be a major WHO conference in Poland on tobacco or health.

Hanne Herborg (Denmark) asked how far EuroPharm had come with data collection. Ida Gustafsen explained that preliminary meetings had been held between the task force managers and the WHO Quality of Care and Technologies unit, which had the expertise in this area. However, the Forum still needed to elaborate the methodology for data collection and data entry as well as make final decisions on which indicators to use.

**Any other business**

**Twinning programme**

Colette McCreedy (United Kingdom), Chairperson for this part of the meeting, introduced the subject of twinning. The overall aim was the improvement of health in countries of central and eastern Europe (CCEE) through a heightened role to be played by pharmacists, which would be achieved through twinning between western European and CCEE pharmaceutical associations. Past willingness on the part of the Forum had not so far led to any real activity for two reasons – money and commitment. However, some funds (US $30 000) had now been received from the Soros Foundation, which the Executive Committee proposed to use to establish three twinning pairs or groups in the Ask about your medicines (QaM) project. These would provide good models for the development of twinning in other areas.

It was recommended that Estonia and Finland should twin in the context of QaM, as they had a natural link and had already shown interest. The Forum needed the names of other countries interested and members were encouraged to show their interest as soon as possible, so that arrangements could be set up early in the new year.

The proposal was put to the Forum and was accepted.

**Presentation of a new project: Pharmacists and HIV/AIDS**

Annick Dulion (France) introduced a project proposal on development of strategies for the activities and priorities of pharmacists in the fight against HIV/AIDS. The project was based on the work carried out by the FIP Working Group on AIDS and Drug Addiction over the past three years to support the activities of pharmacists in helping people with HIV.

The project aimed at developing strategies for the activities and priorities of pharmacists in the fight against the HIV/AIDS pandemic, as well as facilitating the involvement of pharmacists. Ms Dulion presented the results of a survey of ongoing activities in this area in Europe: activities in 14 European countries had yielded 26 examples of experience in 1998–1999 with programmes on needle exchange, substitution therapy, information and prevention. Ms Dulion proposed that these activities should be linked, promoted and coordinated within the Forum.
After discussion the Forum decided to establish the project and the Executive Committee encouraged members to show their interest in becoming involved. The Professional Secretary and Ms Dulion would take the first steps in coordinating and guiding the start-up process. The appointment of a task force manager was postponed until January 2000.

**Addresses by observers**

**European Pharmaceutical Students’ Association**

Mr Arthur Franklin, President of the European Pharmaceutical Students’ Association (EPSA), said that it was a great honour to be at the EuroPharm Forum meeting and outlined the progress of EPSA during the previous year. The Association, which now had 32 member countries, was in its twenty-second year of existence and had established a role as the European body representing students. It aimed to inform students about recent developments and had recently succeeded in collaborating with the International Pharmaceutical Students Federation (IPSF) on developing a booklet entitled *Pharmacy education: a vision for the future*. It was also collaborating with medical students.

**European Industrial Pharmacist Group**

Ms Maria Terese Cosme of the European Industrial Pharmacist Group (EIPG) gave an overhead presentation. She told the Forum that the EIPG represented 7000 pharmacists in European industry, with the objective of trying to influence the evolution of EU regulations and guidelines. The next General Assembly would be in Paris in June 2000.

**European Society of Clinical Pharmacy**

Ms Maria Margarida Caramona described the role of the European Society of Clinical Pharmacy (ESCP) as collaboration with other pharmaceutical associations and providing a European platform for special interest groups. Their next spring conference would be in Reykjavik from 11 to 13 May 2000, and the autumn conference would be held in Basel, Switzerland, from 11 to 14 October 2000.

**Pharmaceutical Care Network Group**

Mr J.W. Foppe van Mil of the Pharmaceutical Care Network Group (PCNE) talked about money and commitment. He explained that PCNE coordinated research in pharmaceutical care in Europe and asked participants to contact PCNE for collaboration as many members of the associations were active in PCNE. In 2001 there would be a Working Conference on process indicators.

Mr Joep Winters, former President of EuroPharm Forum, briefed members about the progress of the initiative by the WHO Regional Office for the Americas/Pan American Health Organization (PAHO) to create a Forum, ending with a Declaration.

**Date and venue of the Ninth Annual Meeting**

The Executive Committee proposed to arrange the Ninth Annual Meeting in Copenhagen, in accordance with the statutes of the Forum, on 20–21 October 2000. The date still needed to be verified with other activities in Copenhagen, but the proposal was put forward to the Forum and agreed.
Conclusions and recommendations

The President outlined the main achievements of the Meeting as follows:

- two new members had joined the Forum from the CCEE and the newly independent states
- observer status had been granted to EAFP
- two new activities had been proposed to the Forum and had been favourably received.

Closure

The President thanked everyone for their participation in both the Eighth Annual Meeting of EuroPharm Forum and the 3rd International Symposium as well as, he hoped, the Asthma Symposium to be held the following day. In particular, he thanked Dr Asvall for his opening address and for active participation throughout the Meeting. He then officially closed the Meeting.

Meet your task force manager

The following morning, simultaneous workshops were held for each of the five EuroPharm Forum projects, chaired by the relevant task force manager. These gave participants the opportunity to discuss the work involved at national level in greater depth. The managers later presented the activities of the workshop and the recommendations made at a general session.
8th Annual Meeting of EuroPharm Forum
Lisbon, Portugal
12-13 November 1999

Provisional Programme

Friday, 12 November 1999

13.30h – 14.00h Registration at
Associação Nacional das Farmácias (ANF)
R. Marechal Saldanha 1, Lisbon

Welcome and opening of the meeting

14.00h – 14.30h
• Hans-Günter Friese,
  President of EuroPharm Forum
• J.E. Asvall, Regional Director, WHO Europe

Business session

14.30h – 15.30h
• Report of the Executive Committee
  Hans-Günter Friese, President

• Financial report
  Reijo Purasmaa, Treasurer
  ✓ Profit and loss account 1998
  ✓ Auditor’s report
  ✓ Budget 1999 - 2000

• Applications for membership and Observer status

15.30h – 16.00h Coffee break

16.00h – 17.00h
• Latest progress and future plans of the projects
  Task force managers

17.00h – 18.00h
• Any other business
  ✓ Twinning programmes
  ✓ Presentation of new project:
    Pharmacists and HIV/AIDS

• Date & venue of next annual meeting
• Conclusions and recommendations of the meeting

18.00h Closure of the meeting

20.30h - Closing dinner
ANNEX 1

Saturday, 13 November 1999

**Professional session**

At Associação Nacional das Farmácias (ANF)

09.00h – 12.30h

**Meet your task force manager**

Five parallel workshops:

- Ask about your medicines project - André Masy
- Asthma services project - Dick Tromp
- CINDI project - Suzete Costa
- Diabetes care project - Maria Augusta Soares
- Smoking cessation project - Ida Gustafsen (stand in for Eeva Teräsvirta)

12.30h – 13.30h

Lunch at ANF

**Satellite Symposium on Asthma Services in European Pharmacies**

13.30h – 13.45h

**Welcome**

_Hans-Günter Friese, President_

**Introduction**

_Dick Tromp, Task force manager_

13.45h – 14.15h

**Modern asthma management and the role of the pharmacist**

_Dr PNR (Richard) Dekhuijzen, MD, chest physician_  
_Academic Hospital Nijmegen, NL_

14.15h – 14.45h

**Country experiences on asthma services**

- France – Florence Guillier
- Germany - Frank Verheyen

14.45h – 15.00h

Coffee break

15.00h – 15.30h

**Linking the projects**

_Ida Gustafsen, Professional Secretary_

15.30h – 16.00h

**Outcomes, processes and structures**

_Dr Carmel Hughes, Northern Ireland_

16.00h – 16.30h

**Results of the survey on Asthma services**

_Dick Tromp, Task force manager_

16.30h

**Closing remarks**

_Ida Gustafsen, Professional Secretary_
EUROPHARM FORUM

ANNUAL REPORT 1999

(October 1998-November 1999)
World Health Organization  
Regional Office for Europe  

EuroPharm Forum Secretariat  
Programme for Pharmaceuticals  

Scherfigsvej 8  
DK-2100 Copenhagen  
Denmark  

Telephone:  +45 3917 1515 or 1330  
Telefax:  +45 3917 1855  
E-mail:  igu@who.dk  or  jtr@who.dk  
Web:  www.who.dk/ch/pha/europha.htm  

---  

**EuroPharm Forum**  
The Forum is a joint network between national pharmaceutical associations and the World Health Organisation Regional Office for Europe. It was founded in 1992 and today associations from 32 countries are members, covering central, eastern and western European countries, as well as the newly independent states.  

---  

**Executive Committee**  
President - Mr Hans-Günter Friese  
Vice President - Ms Maja Jaksevac-Miksa  
Treasurer - Mr Reijo Purasmaa  
Member - Mr Dirk Broeckx  
Member - Ms Mary Ann Sant Fournier  
Member - Ms Suzete Costa  
Member - Ms Colette McCreedy  

**Secretariat**  
Professional Secretary - Ms Ida Gustafsen  
Secretary - Ms Julia Trangeled
# Contents

<table>
<thead>
<tr>
<th>Preface</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Achievements</td>
<td>4</td>
</tr>
<tr>
<td>Projects:</td>
<td></td>
</tr>
<tr>
<td>• Ongoing projects</td>
<td>5</td>
</tr>
<tr>
<td>• New Projects</td>
<td>5</td>
</tr>
<tr>
<td>• Ask about your medicines (QaM)</td>
<td>6</td>
</tr>
<tr>
<td>• Asthma services</td>
<td>7</td>
</tr>
<tr>
<td>• CINDI (Hypertension Management)</td>
<td>8</td>
</tr>
<tr>
<td>• Diabetes care</td>
<td>9</td>
</tr>
<tr>
<td>• Smoking cessation</td>
<td>10</td>
</tr>
<tr>
<td>Activities:</td>
<td>11-12</td>
</tr>
<tr>
<td>• Collaboration with international partners</td>
<td>13</td>
</tr>
<tr>
<td>• Symposia, conferences, seminars etc</td>
<td></td>
</tr>
<tr>
<td>Annual Meetings</td>
<td>14</td>
</tr>
<tr>
<td>The Executive Committee</td>
<td>15</td>
</tr>
<tr>
<td>Members and Observers</td>
<td>16</td>
</tr>
<tr>
<td>Public Relations</td>
<td>17-18</td>
</tr>
<tr>
<td>Evaluation and future</td>
<td>19</td>
</tr>
<tr>
<td>List of Members and Observers</td>
<td></td>
</tr>
</tbody>
</table>
The aim of the Forum is, within the framework of the WHO Health21 policy, to encourage and support:

- the development of pharmacy practice
- the implementation of pharmacy practice projects at national level
- the integration of appropriate aspects of policies of HFA into basic, postgraduate and continuing pharmaceutical education
- the formulation of policy statements on health issues.

The means of achieving these objectives is through establishing a dialogue and co-operation between national pharmaceutical associations and the WHO Regional Office for Europe.

The Forum seeks to improve all aspects of dealing with health and high priority has been given to increasing the contribution of pharmacists in promoting healthy lifestyles among the public and to establish the pharmacists central role in the provision of advice and information, as well as an effective co-operation between pharmacists, prescribers and other health professionals.

From the outset, the focus within the Forum has been on practice projects designed to document the benefit of the involvement of pharmacists in improving patient care, by ensuring patients get maximum benefit from their medicines by establishing lifestyle counselling services. We are currently running five projects and formal collaboration with other international networks and WHO units has been established and extended in the past years, mainly through these projects.

This report presents our activities in the period from October 1998 – October 1999.

The Executive Committee is pleased with the remarkable achievements made by the Forum in the previous years and with the increased visibility gained. The activities of the Forum have been further developed by updating existing programmes and elaborating two new projects to be introduced to the Forum at the 8th Annual Meeting.

The financial consequence of all the work involved is quite substantial and the Executive Committee therefore greatly appreciates the Forum’s approval of the new membership fee structure, which took effect from 1999. This has, together with the generous one-off payments from many of our members, ensured a better financial basis for the Forum and its activities.

There is a growing interest in the EuroPharm Forum concept from pharmaceutical organisations within other WHO Regions and the Executive Committee welcomes the fact that initiatives have been taken to establish a Pharmaceutical Forum of the Americas. Mr Joep Winters, former President of EuroPharm Forum, has played a significant role in facilitating this process.
Main achievements

The main achievements in 1999 are listed below. They are explained in more detail later in the report:

- A Declaration on Pharmaceutical service and educational needs has been issued
- Two project protocols have been published as official WHO documents, with the newly designed EuroPharm Forum cover
- External funding has been obtained for setting up twinning programmes
- The application for EU funds to make a survey on pharmacists’ smoking habits and their interest in smoking cessation activities has been sent to the Europe Against Cancer Programme, through the European Network for Smoking Prevention, which has evaluated our project proposal positively
- A Training seminar on hypertension management was held and a special CINDI newsletter was subsequently issued
- The EuroPharm website has been further developed and an increasing number of interested partners and individuals request material
- Two new Members and one Observer have joined the Forum and still more applications are received
Projects

Ongoing projects
At the present time EuroPharm Forum is running five projects conducted through community pharmacies to manage medicines and promote good health - Ask about your medicines (QaM), Asthma services, CINDI (hypertension management), Diabetes care and Smoking cessation. All the projects have focused on pharmaceutical care and how to establish lifestyle counselling services and document the benefit of involving pharmacists.

A short update on each of the projects can be found on the following pages.

New projects
Pharmacists and HIV/AIDS
The Executive Committee recommends the Forum to establish a new project on Pharmacists and AIDS following an invitation by the FIP Working Group to collaborate on developing European strategies within the project: Towards the pharmacy as an AIDS/HIV care centre.

The FIP Working Group on AIDS and Drug Addiction has developed the project over the past three years to support the activities of pharmacists in helping people with HIV. Furthermore, much work has been done to collect information about the needs of various populations and to help the pharmacists to meet these needs. In this project, FIP and WHO will supplement the initial achievements of the Working Group by supporting pharmacists to become HIV/AIDS centres.

A EuroPharm survey on ongoing activities within this area has already been prepared, the results of which are presented at the 8th Annual Meeting. The Executive Committee recommends that Annick Dulion from France, who has been at the centre of the FIP project, be appointed as task force manager.

Twinning
A project proposal for a twinning project has been developed and will be presented to the Forum at the 8th Annual Meeting. The aim is to improve health in CEE countries through an increased role of the pharmacists which should be achieved by twinning pharmaceutical associations from Western European countries with those in CEE countries, in order to enhance the status and raise the technical profiles of these associations. External funding has been obtained for this project with a total amount of USD 30,000 granted by the Soros Foundation. The Executive Committee considers that the money is sufficient to establish 3 twinning pairs or groups and would like the money to be used in a defined project, e.g. the QaM project.

---

1 An autonomous non profit organization founded by George Soros
Projects

Ask about your medicines (QaM)

Task force manager: Mr A. Masy, Belgium

The project is designed to encourage members of the public to seek information to help them derive maximum therapeutic benefit from a course of medication. The project has attracted much attention from member associations since its start in 1993.

At the one-day Training seminar “Questions about Medicines” in February 1998, it was recommended that the 1993 QaM Campaign Proposal be updated and include a guideline on how to run the project, together with a model for evaluation. It was also recommended to develop a strategy for the task force in order to keep the projects running and to learn from each other to get a better outcome.

The task force manager has updated the Campaign Proposal to bring it into line with other project protocols, and is currently working on a guideline to include three levels. This will be sent to the task force members and other experts for review and comments in the near future. Furthermore, a model for evaluation is now being developed, with support from the WHO Quality of Care and Technologies unit (QCT).

Twinning programmes are planned to be established within this project next year, financially supported by the grant from the Soros Foundation.

Number of countries participating: 13
Belgium, Croatia, Denmark, Finland, France, Italy, Latvia, Malta, Portugal, Slovenia, Spain, Sweden, United Kingdom
Projects

Asthma Services

Task force manager: Dr D. Tromp, The Netherlands

The project aims to support pharmacists in dealing with asthma patients in everyday practice at the pharmacy and the task force was established in 1996. The Pharmacy-based Asthma services, Protocol and Guidelines was adopted by the Forum in 1997 and is now available as an official WHO document. The main focus of the Protocol is to provide a systematic and structured approach to pharmacy-based asthma services, including documentation of the pharmacy services, their outcomes and implementation strategies. Furthermore, the purpose is to provide member associations with a tool for national implementation of pharmacy-based asthma services within the framework of Good Pharmacy Practice (GPP).

During a Training Seminar in 1998, a strategy for the implementation of the project was discussed. However, as practice varies from country to country, it was decided that the strategy should build on experiences from those countries implementing the services. Since then the task force manager has tried to find a feasible structure to control and check the country activities. The Quality Model of Donabedian, upon which GPP is based, seems to be useful to divide activities, outcomes and structures at various levels and can also be used for the activities within the asthma project. Furthermore, a database can be created from this model.

A questionnaire, based on this model, was recently sent out to task force members to analyse the situation and the results of this survey will be presented at the Symposium in Lisbon.

The task force has organized a satellite symposium on Asthma Services in European Pharmacies in Lisbon on 13 November 1999. The objectives of the Symposium are to exchange information and share experiences and to present and compare the first results of the interventions in pharmacies. Participants will mainly be task force members and representatives from other organisations.

A specific asthma project newsletter, including information and the provisional programme of the Asthma symposium, has recently been sent out by the task force manager.

Number of countries participating: 11
Belgium, Denmark, Finland, France, Germany, Ireland, Malta, The Netherlands, Portugal, Turkey, United Kingdom
Projects

CINDI (Hypertension management)

Task force manager: Ms S. Costa, Portugal

The project is based on a multidisciplinary approach and aims at achieving an optimal hypertension control through a more active involvement of pharmacists in the prevention, detection and management of hypertension. The task force was established in 1996, as a result of the ongoing collaboration between the WHO CINDI Programme and EuroPharm Forum.

The purpose of this collaboration was to enhance the effectiveness of health promotion and disease prevention through an improved collaboration among various groups of health professionals and, as a first step, a project on a pharmacy-based hypertension management model was developed.

A project protocol has been developed. It is mainly addressed to community pharmacists and designed to improve hypertension control at community level: It is meant to be used as a guide when organising pharmacy-based work within hypertension management. The Pharmacy-based hypertension management, Protocol and guidelines, was approved by the Forum in 1998 and should now be tested in a feasibility study, then revised accordingly before broader use. Unfortunately, the study is dependent on obtaining funds which, so far, has been unsuccessful.

It was, however, decided to run a training seminar, to maintain motivation and enthusiasm demonstrated by various countries. The two-day Seminar took place in May 1998 and was attended by 13 pharmacists from 10 member associations already running, or interested in running, a hypertension management programme. Included in the Seminar was a highly interactive workshop, during which participants had the opportunity to present current pharmacy-based hypertension management activities taking place in their countries and to share experiences. A summary of these presentations was published in a special Newsletter of EuroPharm Forum issued in August 1999.

Number of countries participating: 16
Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Latvia, Malta, The Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, United Kingdom
Projects

Diabetes care

Task force manager: Dr M.A. Soares, Portugal

The PharmaDiaβ Programme has been running since 1993 and aims to improve the quality of diabetes care by integrating the pharmacist in national diabetes programmes. The programme has been developed in collaboration with the St Vincent Declaration Action Programme (SVD) and outlines recommendations and concrete ideas on how pharmacists can implement the Guidelines at national level.

The task force manager has, for several years, acted as Convenor of the SVD working group on the role of the pharmacist in the St Vincent team. In that capacity, she has prepared and chaired the workshops for the above group and developed a European study on the involvement of pharmacists in diabetes care, presented at the 5th SVD meeting in 1999.

Evaluation of the pharmacists’ involvement in diabetes care at national level has been given high priority during the last year. Key indicators have been identified and an evaluation form – the BISP (Basis Information Sheet for Pharmacists) – has been finalised, with technical support from the WHO Quality of Care and Technologies unit (QCT). The form includes indicators from the WHO well-being scale.

The PharmaDiaβ Programme is now being updated and the revised version will include the evaluation form. Furthermore, based on the positive results from Portugal, a strategy on how to keep the pharmacists motivated and interested in running the PharmaDiaβ Programme has been outlined.

Number of countries participating: 11
Belgium, Croatia, Denmark, Finland, France, Ireland, Latvia, Malta, Portugal, Turkey, United Kingdom
Projects

Smoking cessation

Task force manager: Ms E. Teräsalmi, Finland

The project has been running since 1993 and aims at involving pharmacists in smoking cessation programmes in the communities they serve. The document *The Role of the Pharmacist in Smoking Cessation*, including the *Pharmacists' Charter on action against smoking*, was formally adopted by the Forum in 1996. It was revised in 1998 and included in the Smoke-free Europe series as booklet No 12 with the title: *Pharmacists and action on tobacco*.

In 1998, a joint project was started between the three forums of health professionals and WHO together with the Tobacco or Health Programme. This aims at reducing the prevalence of smoking among health service users and health professionals and in 1999 two subprojects were started.

One of the subprojects is a survey on pharmacists’ smoking habits and their interest in smoking cessation activities, for which we have applied for EU funds. The application went through the European Network on Smoking Prevention (ENSP) to the Europe against Cancer program. ENSP has evaluated our project proposal positively and included the survey in the ENSP framework project, comprising around 13 different projects. Accordingly, EuroPharm was invited to participate in a project building workshop in Brussels focusing the co-ordination and communication between the project leaders and ENSP as all projects are linked together in one framework project. The survey should cover the EU countries and all our member associations in the EU have been encouraged to participate. In addition, a meeting was arranged during the FIP Congress in Barcelona for participating countries to explain their role in this survey.

Another subproject is a study of the effectiveness of local co-operation concerning smoking cessation. It should be carried out in several countries and aims to find out whether health professionals can get better results in smoking cessation by working together in a community. The research has now been started in Finland, with the basic questionnaire being analysed and the work in local networks begun. The project was presented at the FIP Congress with a poster.

A WHO European Partnership Project on Tobacco Dependence has been set up with the objective of reducing tobacco-related death and disease among tobacco-dependent smokers and EuroPharm Forum is represented in the Project Group. The project is supported by both non-governmental and governmental agencies, including the Commission of the European Union and its strength is that it has brought together three major pharmaceutical companies, Glaxo Wellcome, Novartis Consumer Health and Pharmacia & Upjohn, to support a common goal that will have a significant impact on public health.

*Number of countries participating: 14*

*Belgium, Croatia, Denmark, Finland, France, Germany, Israel, Latvia, Malta, Portugal, Slovenia, Spain, Sweden, United Kingdom*
Activities

Collaboration with international partners

WHO networks

- Partnerships in Health and Emergency Assistance (PAR)
  Co-operation between PAR and EuroPharm Forum started in 1998. The purpose is to discuss the rationale and benefits of an active involvement of pharmacists and their associations in humanitarian assistance in emergencies and post-emergencies, as well as disaster preparedness. As a first concrete step of this collaboration, the WHO Guidelines on Drug Donations was disseminated to the member associations of the Forum in order to alert decision-makers and the public to the problems often resulting from drug donations.

- Tobacco or Health (TOH)
  The ongoing collaboration with TOH, which is mainly through the joint project which includes the European Forum of Medical Associations (EFMA) and the European Forum of Nursing and Midwifery Associations (EFNMA), has been strengthened in the past year through the WHO European Partnership Project on Tobacco Dependence. The project was set up with the objective of reducing tobacco-related death and disease among tobacco-dependent smokers and EuroPharm Forum is represented in the Project Group. Additionally, the EuroPharm project protocol on *The role of the pharmacist in smoking cessation* was, in 1998, included in the Smoke-free Europe series as Booklet No 12, published by TOH, entitled: *Pharmacists and action on tobacco*.

- CINDI Programme
  Collaboration with the CINDI programme has been further developed through the Joint CINDI/EuroPharm Forum Project on hypertension management. The main purpose of this collaboration is to enhance the effectiveness of health promotion and disease prevention by improving collaboration among various groups of health professionals (see Projects - CINDI).

- St Vincent Declaration (SVD) Action programme
  EuroPharm Forum has now worked together with SVD for several years. Recent developments are described under Projects - Diabetes care.

- Quality of Care and Technologies (QCT)
  QCT is assisting the task force managers and the Professional Secretary in identifying key indicators and methods to collect and manage data which has been given high priority within our projects.

- Sexually Transmitted Diseases and HIV/AIDS (ASD)
  The Executive Committee has investigated the possibility of setting up a new project on Pharmacists and HIV/AIDS. To benefit from experiences in this field and to ensure an integrated approach, the Forum has recently started a collaboration with ASD.
Other partners

- Pharmaceutical Care Network Europe (PCNE)
  The collaboration with PCNE has continued during the past year and has now been extended by granting PCNE observer status of the Forum. Different models of collaboration, e.g. EuroPharm serving as a platform for implementation of the projects developed by PCNE, are being discussed, in order to facilitate the sharing of experiences.
  Furthermore the five EuroPharm task force managers, together with the Professional Secretary, attended the PCNE Working Conference on Outcome Measurements in Pharmaceutical Care.

- Ludwig Boltzmann Institute for the Sociology of Health and Medicine (LBISHM), Vienna.
  At the Seventh Annual Meeting, a new European project was introduced to the Forum by Professor Jürgen Pelikan from LBISHM. The project, the short title of which is *Health Promotion in Primary Health Care: General Practice and Community Pharmacy*, aims at creating synergies, facilitating the exchange of experiences and spreading models of good and best practice all over Europe. It is commissioned and funded by the European Commission DGV. The Forum acts as European Supporting Partner of the project and is represented by the Professional Secretary who acts as an observer in the working party of experts.

- European Network on Smoking Prevention (ENSP)
  The Forum has recently started collaboration with ENSP as a result of the application for EU funds which went through ENSP. See Projects - Smoking cessation.

Observer organizations

- The Pharmaceutical Group of the European Union (PGEU)
  A closer working relationship between PGEU and the Forum was initiated in 1999. The collaboration will be continued and further developed in the coming years with annual meetings of the executive committees and information-sharing on key points through the secretariats.

- European Pharmaceutical Students’ Association (EPSA)
  The Executive Committee has recently discussed how a closer collaboration could be established with EPSA, particularly through the task forces. It was decided to invite EPSA, together with the world-wide students’ organization IPSF, to nominate observer representatives to the task forces.

- European Society of Clinical Pharmacy (ESCP)
  Discussions have taken place in previous years on possible collaboration with ESCP which has now led to a concrete proposal from ESCP on closer and more frequent communication, as well as a closer contact between the ESCP Special Interests Groups and the EFPA task forces. This has been positively received by the Executive Committee and will be followed up in the near future.
Activities

Symposia, conferences, seminars etc.

3rd International Symposium
EuroPharm Forum has organized international symposia over a number of years. This year, the 3rd one is to be held in Lisbon on The Role of the Pharmacist in Health Promotion and Disease Prevention. It is organized jointly with the two national pharmaceutical associations in Portugal, in association with FIP and PGEU.

CINDI Training seminar
Following the success of the training seminars in 1998, a further seminar was held in May 1999 for those countries which are interested in running hypertension management services in community pharmacies in their countries. The Seminar was organized by the CINDI task force manager, together with the Secretariat, and aimed at training the participants in managing the project. As part of the Seminar, a workshop was arranged, during which the participants had the opportunity to present their own pharmacy-based activities and share experiences. Subsequently, a special EuroPharm Newsletter presenting these country activities was published.

Symposium on Asthma Services in European Pharmacies
The task force has organized a symposium on Asthma Services in European Pharmacies in Lisbon on 13 November 1999, as a satellite to the 3rd International Symposium. The objectives of the Symposium are to exchange information and share experiences and to present and compare the first results of the interventions in pharmacies. Participants will mainly be task force members and representatives from other organisations.
7th Annual Meeting
The 7th Annual Meeting of EuroPharm Forum took place in Copenhagen on 6-7 November 1998 with the highest participation ever: 84 representatives from 29 countries. As usual, the Meeting comprised Business and Professional sessions, including reports on activities carried out in the previous year and proposals for future activities. For the second time, a poster exhibition was included and although relatively few countries participated, those which did produced posters on some very topical subjects which created much interest from the participants.

During the business part of the meeting, elections were held for new officers of the Executive Committee and Mr Joep Winters handed over the Presidency to Mr Hans-Günter Friese. Applications for membership from pharmaceutical associations in The Former Yugoslav Republic of Macedonia and the Republic of Moldova were approved at the meeting. Furthermore a proposal for a new membership fee structure was accepted by the Forum, ensuring a better financial basis for the future.

The theme of the Professional session was divided into two parts: Pharmaceutical service and educational needs and Pharmaceutical service in practice. Seven speakers contributed to the first part, which was chaired by Prof. Th.F.J.Tromp and aimed at outlining some recommendations on ways to implement curricular change. These recommendations were included in a Declaration which was finally adopted by member associations in June 1999. The second part comprised two project-related topics – the Third Action Plan for a Tobacco-free Europe and Pharmacy-based hypertension management and was chaired by Mr Joao Silveira.

The theme was followed by reports on latest progress and future plans of the five projects and the session Meet your task force manager, at which the publication Smoke-free Europe 12: Pharmacists and Action on Tobacco was presented.

The final Report of the 7th Annual Meeting of EuroPharm Forum has been sent to the member associations and to date, no amendments have been suggested.

8th Annual Meeting
The 8th Annual Meeting will take place in Lisbon on 12-13 November 1999 and is linked to the 3rd International Symposium on the Role of the Pharmacist in Health Promotion and Disease Prevention.

The Professional Session comprises five parallel project workshops and a Symposium on Asthma Services in European Pharmacies, organized by the task force manager of the Asthma services project, Dick Tromp. During the Business session, applications for membership from two pharmaceutical associations will be tabled together with one application for observer status.
The Executive Committee

At the 7th Annual Meeting in November 1998 elections were held for a new Executive Committee which now comprises:

- President  - Mr Hans-Günter Friese (Germany)
- Vice President - Ms Maja Jaksevac-Miksa (Croatia)
- Treasurer - Mr Reijo Purasmaa (Finland)
- Member - Mr Dirk Broeckx (Belgium)
- Member - Ms Mary Ann Sant Fournier (Malta)
- Member - Ms Suzete Costa (Portugal)
- Member - Ms Colette McCreedy (United Kingdom)

Meetings

The Executive Committee has held three meetings in 1999 - January, May and September, all of which took place at the World Health Organization, Regional Office for Europe in Copenhagen. In addition, a short meeting will take place in November during the 8th Annual Meeting in Lisbon.

The five task force managers of EuroPharm Forum were invited to join the meetings to report on the status and progress of the projects and in this connection, separate task force managers meetings were held on general matters and in particular how to implement the projects and measure the outcome.

In conjunction with the Executive Committee meeting in May, a separate meeting was held with members of the Executive Committee of PGEU, to discuss how to establish a closer working relationship between the two organisations.
Members and Observers

Membership
Applications for membership from pharmaceutical associations in The Republic of Moldova and The Former Yugoslav Republic of Macedonia were approved in 1998. Unfortunately, the Forum had to exclude Greece from membership, due to insufficient payment of the membership fee, so today pharmaceutical associations from 32 of the 51 Member States in the European Region are members, among which are 7 countries from central and eastern Europe, 3 from the Baltic’s and 2 newly independent states. (Annex 1)

Still more associations have sought to join the Forum and applications from two associations, the Russian Pharmaceutical Association and the Czech Chamber of Pharmacists, will be tabled for approval at the 8th Annual Meeting.

Membership fee
In order to balance the budget and ensure a better financial basis for the Forum and its activities in the future, a new membership fee structure to take effect from 1999 was accepted by the Forum at the Seventh Annual Meeting.

The new membership fees are as follows:

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount USD</th>
<th>No. of countries</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>10,000</td>
<td>6</td>
<td>France, Germany, Italy, Spain, Turkey, United Kingdom</td>
</tr>
<tr>
<td>B</td>
<td>5,000</td>
<td>11</td>
<td>Austria, Belgium, Denmark, Finland, Ireland, Israel, Netherlands, Norway, Portugal, Sweden, Switzerland</td>
</tr>
<tr>
<td>C</td>
<td>1,000</td>
<td>3</td>
<td>Iceland, Luxembourg, Malta</td>
</tr>
<tr>
<td>D</td>
<td>600</td>
<td>12</td>
<td>Albania, Croatia, Estonia, Georgia, Hungary, Latvia, Lithuania, TFYR of Macedonia, Republic of Moldova, Poland, Romania, Slovenia</td>
</tr>
</tbody>
</table>

The Executive Committee regularly reviews the status of the membership fee payments and outstanding fees have been discussed. Reasonable written grounds for non-payment/insufficient payment are now required, on the basis of which the Executive Committee will, each year, assess whether it is acceptable for a country not to pay and still remain a member.

Observers
Observer status was granted in 1998 to the European Forum of Nursing and Midwifery Associations (EFNMA) and the Pharmaceutical Care Network in Europe (PCNE) bringing the total number of observer organisations to nine.

The European Association of Faculties of Pharmacies (EAFP) has applied for observer status and the application will be tabled for approval at the 8th Annual Meeting.
Public relations

The Newsletter

The EuroPharm Forum Newsletter was issued in December 1998 and June 1999 and sent to Members and Observers. In addition, it is sent to a growing number of subscribers representing a variety of individual health professionals, as well as public and private organisations. The Newsletter is also available on the Web: www.who.dk/ch/pha/europha.htm

A EuroPharm Forum Special Edition Newsletter presenting country activities on hypertension management services was issued in August 1999.

Reports and publications

A standard layout for EuroPharm Forum documents has been designed and two project protocols have been published as official WHO documents with the new cover, i.e. Smoke-free Europe 12: Pharmacists and action on tobacco and Pharmacy-based asthma services, Protocol and guidelines.

Articles and posters

Articles on the Forum have been published in several national pharmaceutical journals in Europe. In addition, an article on activities within the Diabetes care project has been published in the St.Vincent Declaration anniversary newsletter.

Posters on EuroPharm Forum project activities have been presented at the following congresses:

- International Congress on Clinical Pharmacy, USA (Diabetes care)
- The 2nd European Conference on Tobacco or Health, Canary Islands (Smoking cessation)
- FIP Congress in Barcelona, Spain (Smoking cessation)
- 5th SVD Meeting, Turkey (Diabetes care)

Web page

The EuroPharm Forum website was introduced in 1998 on the WHO web, as part of the Programme for Pharmaceuticals website. It currently contains general information on the Forum and the Newsletter, as well as latest news. It will be further developed in the near future.
External representation and lectures

Executive Committee members, the Professional Secretary or task force managers have represented EuroPharm Forum at the following events:

- Second Annual Meeting of the European Forum of Nursing and Midwifery Associations in Denmark
- Worldwide course for pharmacy students and newly graduates in International Health Care in Denmark*
- The WHO European Partnership Project on Tobacco Dependence – Project Group meetings
- 1st Expert meeting of the European project on Health Promotion in Primary Health Care, Austria
- PCNE Working Conference 1999, Denmark
- TUPP workshop in Denmark (TUPP – The User Perspective Project)
- ENSP Workshop on project building, Belgium
- 22nd EPSA Congress, Malta*
- The Annual Symposium of the Pharmaceutical Society, Slovenia*
- PGEU General Assembly meeting, Luxembourg*
- International Congress on Clinical Pharmacy, USA
- 59th FIP World Pharmacy Congress, including Council meetings, Spain
- Pharmaceutical Care Network in Europe meetings, Denmark and Spain
- 49th session of the WHO Regional Committee for Europe, Italy
- A GPP seminar, Bosnia and Herzegovina*
- NLN Conference 1999 - Medicines on the Internet, Denmark*
- 5th SVD Meeting, Turkey*

* indicates that a lecture or presentation has been given

In addition, several information meetings on the Forum and its activities and/or addressing possibilities of collaboration have taken place.
Evaluation and future

Remarkable results have been made by the Forum in the past years. The activities of the Forum have been further developed by updating existing programmes and elaborating two new projects to be introduced to the Forum at the 8th Annual Meeting.

An increased visibility of the Forum has been obtained, not least due to the website, and an increasing number of interested partners and individuals are contacting the Secretariat and requesting information in general and about membership. In addition there is a growing interest for the Newsletter.

The collaboration with other international partners and WHO units has been continued and extended, e.g. via involvement in the European project on Health Promotion in Primary Health Care in Vienna and through the ENSP framework project within tobacco control.

In addition, initiatives have been taken to establish a closer collaboration with the students’ organizations and the European Society of Clinical Pharmacy through our projects.

Future plans

Within these first years in the life of EuroPharm Forum, considerable progress has been achieved. However, the success of the initiatives will depend entirely on how individual members react to the opportunities offered and to the possibilities of keeping the motivation and interest in running the projects and implementing the new services. Much attention has therefore been paid, within the task forces, to outline a strategy on how to carry on the projects and implement the service in the everyday practice. There is, however, still a long way to go before this is achieved.

To document what we are doing and to succeed in convincing governments of the benefits of pharmacists’ intervention, the commitment of all members is needed, both in joining the task forces and in implementing the practice models at national level. The Forum therefore continues training pharmacists to implement the projects.

The focus in the coming years will be on the establishment of twinning programmes within the Ask about your medicines project and the elaboration of the project Pharmacists and HIV/AIDS. In addition, the implementation and consolidation of the current activities will still be given high priority.

Dissemination of information to Members and Observers will also be in focus and in this respect we are currently elaborating a new model to ensure more frequent and up to date information is given.
Members and Observers

**Member countries**

Albania  
Austria  
Belgium  
Croatia  
Denmark  
Estonia  
Finland  
France  
Georgia  
Germany  
Hungary  
Iceland  
Ireland  
Israel  
Italy  
Latvia  
Lithuania  
Luxembourg  
Macedonia (The Former Yugoslav Republic of)  
Malta  
Moldova (Republic of)  
Netherlands  
Norway  
Poland  
Portugal  
Romania  
Slovenia  
Spain  
Sweden  
Switzerland  
Turkey  
United Kingdom.

**Observer organizations**

European Association of Hospital Pharmacists (EAHP)  
European Forum of Medical Associations and WHO (EFMA)  
European Forum of Nursing and Midwifery Associations and WHO (EFNMA)  
European Industrial Pharmacist Group (EIPG)  
European Pharmaceutical Students' Association (EPSA)  
European Society of Clinical Pharmacy (ESCP)  
International Pharmaceutical Federation (FIP)  
Pharmaceutical Care Network Europe (PCNE)  
Pharmaceutical Group of the European Union (PGEU)
## EuroPharm Forum - 1998

### Profit & Loss 1998

<table>
<thead>
<tr>
<th>Description</th>
<th>Income</th>
<th>Expenses</th>
<th>US$ account</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO contribution (biennium 98/99)</td>
<td>25,000</td>
<td></td>
<td>22,462</td>
</tr>
<tr>
<td>Membership fees</td>
<td>65,713</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bank Interest</td>
<td>1,543</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One-off payments</td>
<td>49,150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training Seminar - Feb.</td>
<td>19,363</td>
<td>18,619</td>
<td>111,606, 16,413</td>
</tr>
<tr>
<td>Annual meeting</td>
<td>20,007</td>
<td>29,006</td>
<td>128,554, 18,365</td>
</tr>
<tr>
<td>Secretariat administration</td>
<td></td>
<td>31,030</td>
<td></td>
</tr>
<tr>
<td>Project coordination/technical assistance</td>
<td></td>
<td>47,970</td>
<td></td>
</tr>
<tr>
<td>Meetings/Travel - general</td>
<td></td>
<td>5,135</td>
<td></td>
</tr>
<tr>
<td>Meetings/Travel - project</td>
<td></td>
<td>6,935</td>
<td></td>
</tr>
<tr>
<td>Newsletter/brochure</td>
<td></td>
<td>3,754</td>
<td></td>
</tr>
<tr>
<td>WHO Administration cost</td>
<td></td>
<td>8,600</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous - general</td>
<td>602</td>
<td></td>
<td>*Exchange rate at 01.01.98 US$ 1 = 6.8 DKK</td>
</tr>
<tr>
<td>Miscellaneous - project</td>
<td>3,509</td>
<td></td>
<td>*Exchange rate at 31.12.98 US$ 1 = 7.0 DKK</td>
</tr>
<tr>
<td>Bank fees</td>
<td></td>
<td>25</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>180,776</td>
<td>155,185</td>
<td></td>
</tr>
<tr>
<td><strong>Profit</strong></td>
<td></td>
<td>25,591</td>
<td></td>
</tr>
<tr>
<td><strong>Balance</strong></td>
<td>180,776</td>
<td>180,776</td>
<td></td>
</tr>
</tbody>
</table>

All figures in US $

### Bank status 1998

<table>
<thead>
<tr>
<th>Description</th>
<th>01.01.98</th>
<th>31.12.98</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank balance as at 01.01.98</td>
<td>22,462</td>
<td>1,095</td>
</tr>
<tr>
<td>Bank balance as at 31.12.98</td>
<td></td>
<td>1,095</td>
</tr>
<tr>
<td>DKK account *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Exchange rate at 01.01.98 US$ 1 = 6.8 DKK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Exchange rate at 31.12.98 US$ 1 = 7.0 DKK</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Profit/Loss 1998 (Annex 3)
### Finances

<table>
<thead>
<tr>
<th>Description</th>
<th>IN</th>
<th>US$</th>
<th>OUT</th>
<th>US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration fees</td>
<td>17961 DKK</td>
<td>14913 US$</td>
<td>130472 DKK</td>
<td>8840 US$</td>
</tr>
<tr>
<td>Sponsorship - Assoc. Danish Pharmacists</td>
<td>15000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Binders/dividers (80)</td>
<td></td>
<td>1160</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice Boards 8 @ 135 DKK</td>
<td></td>
<td>1080</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buses - 5 &amp; 6 Nov.</td>
<td></td>
<td>4537</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee at WHO - 6 Nov</td>
<td></td>
<td>1680</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch at WHO - 6 Nov</td>
<td></td>
<td>6720</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dinner at Royal Copenhagen - 6 Nov</td>
<td></td>
<td>48720</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference package at Scandic Hotel</td>
<td></td>
<td>36260</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel - external speakers</td>
<td></td>
<td>2960</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Photographs developed</td>
<td></td>
<td>130</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accomm.Scandic Hotel (speakers/sec)</td>
<td></td>
<td>10380</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFA Executive Summary - 100 @ 1$</td>
<td></td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel - CCEE</td>
<td></td>
<td>5780</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accommodation - CCEE</td>
<td></td>
<td>19805</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Conversion to US$</strong></td>
<td>32961 DKK</td>
<td>14913 US$</td>
<td>130472 DKK</td>
<td>8840 US$</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td>20007</td>
<td>20166</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## EUROPHARM FORUM - BANK INTEREST 1998

<table>
<thead>
<tr>
<th>Description</th>
<th>DKK</th>
<th>US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statements of interest Jan-Dec 98 (A/C 5005821621)</td>
<td>1,556.08</td>
<td></td>
</tr>
<tr>
<td>Kontooversigt per. 31 Dec. 98 (A/C 6262762279)</td>
<td>-90.25</td>
<td>-13.00</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,543.08</strong></td>
<td></td>
</tr>
</tbody>
</table>
# EUROPHARM FORUM - 1998

## Meetings/Travel - General

<table>
<thead>
<tr>
<th>Place</th>
<th>Name</th>
<th>Reason</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amsterdam</td>
<td>Ida Gustafsen</td>
<td>ExCom meeting</td>
<td>927</td>
</tr>
<tr>
<td>Amsterdam</td>
<td>Julia Trangeled</td>
<td>ExCom meeting</td>
<td>780</td>
</tr>
<tr>
<td>Amsterdam</td>
<td>ExCom/Secretariat</td>
<td>Payment for conference room</td>
<td>635</td>
</tr>
<tr>
<td>Vienna</td>
<td>Ida Gustafsen</td>
<td>EU project - European expert meeting</td>
<td>1,444</td>
</tr>
<tr>
<td>Russia</td>
<td>Maja Jaksevac-Miksa</td>
<td>Meeting with Pharm. Association</td>
<td>1,349</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Total</strong></td>
<td><strong>5,135</strong></td>
</tr>
</tbody>
</table>

## Meetings/Travel - Project

<table>
<thead>
<tr>
<th>Place</th>
<th>Name</th>
<th>Reason</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiff, UK</td>
<td>Ida Gustafsen</td>
<td>Participation in smoking Conference</td>
<td>1,536</td>
</tr>
<tr>
<td>Cardiff, UK</td>
<td>Gustafsen/Teräsalmi</td>
<td>Registration fee for smoking conference - 8052 DKK (Teräsalmi to reimburse half)</td>
<td>1,150</td>
</tr>
<tr>
<td>Hague</td>
<td>Ida Gustafsen</td>
<td>Registration fee for PPSI conference (paid in cash)</td>
<td>100</td>
</tr>
<tr>
<td>Hague</td>
<td>Ida Gustafsen</td>
<td></td>
<td>1,923</td>
</tr>
<tr>
<td>Geneva</td>
<td>Ida Gustafsen</td>
<td></td>
<td>1,493</td>
</tr>
<tr>
<td>Denmark</td>
<td>Ida Gustafsen</td>
<td>Registration fee for PCNE workshop - Hilleroed, Denmark in Feb.99</td>
<td>733</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Total</strong></td>
<td><strong>6,935</strong></td>
</tr>
</tbody>
</table>
### Miscellaneous - General

<table>
<thead>
<tr>
<th>Service</th>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postage</td>
<td>Report of the 6th Annual Meeting</td>
<td>145</td>
</tr>
<tr>
<td>Postage</td>
<td>Background documents to 7th Annual Meeting</td>
<td>254</td>
</tr>
<tr>
<td>Postage</td>
<td>General</td>
<td>76</td>
</tr>
<tr>
<td>Coffee</td>
<td>ExCom meetings</td>
<td>45</td>
</tr>
<tr>
<td>Postage</td>
<td>General</td>
<td>26</td>
</tr>
<tr>
<td>Printing</td>
<td>Coloured overheads</td>
<td>56</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>602</strong></td>
</tr>
</tbody>
</table>

### Miscellaneous - Projects

<table>
<thead>
<tr>
<th>Service</th>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postage</td>
<td>Asthma Protocols</td>
<td>446</td>
</tr>
<tr>
<td>Printer</td>
<td>Asthma Binders</td>
<td>2548</td>
</tr>
<tr>
<td>Secondment</td>
<td>Eeva Teräsalmi - Lump sum payment</td>
<td>515</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>3509</strong></td>
</tr>
</tbody>
</table>
**EUROPHARM FORUM - 1998**

Secretarial Administration and Project Coordination/Technical Assistance

<table>
<thead>
<tr>
<th>Secretarial Administration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secretary</strong></td>
<td>25,700</td>
</tr>
<tr>
<td>10% Professional Secretary</td>
<td>5,330</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>31,030</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project Coordination/Technical Assistance</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>90% Professional Secretary</td>
<td>47,970</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>47,970</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secretary (75%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan. - 12 Feb.</td>
<td>2,939</td>
</tr>
<tr>
<td>20 Feb. - 31 Aug.</td>
<td>13,333</td>
</tr>
<tr>
<td>01 Sep. - 27 Jan. 99</td>
<td>10,895</td>
</tr>
<tr>
<td>Overtime - Nov.</td>
<td>528</td>
</tr>
<tr>
<td>Sub total</td>
<td>27,695</td>
</tr>
<tr>
<td>01 - 27 Jan.</td>
<td>1,995</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>25,700</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Professional Secretary (50/75%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan. - 30 Apr.</td>
<td>13,109</td>
</tr>
<tr>
<td>01 May - 23 Jun.</td>
<td>9,695</td>
</tr>
<tr>
<td>01 Jul. - 31 Dec.</td>
<td>5,496</td>
</tr>
<tr>
<td>WHO biennium contribution</td>
<td>25,000</td>
</tr>
<tr>
<td>WHO biennium contribution</td>
<td>25,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>53,300</strong></td>
</tr>
</tbody>
</table>
Profit & Loss 1998
Explanatory notes

Line 1
- The WHO contribution of USD 25,000 is for the biennium 1998-99 but was received and used as a lump sum in 1998 which is now reflected here.

Line 2
- The membership fees of USD 65,713 also include the fees, which were paid in December 1997. These prepaid fees were included in the bank balance of last year.

Line 5
- The Training seminar showed a small profit of USD 744 which was included in the revised budget.

Line 6
- The loss of USD 8,999 for the Annual Meeting was less than the budgeted USD 10,000 for financial assistance to the annual meeting.

Line 7 and 8
- The figures are lower than in the accepted budget which included two 75% contracts but the Professional Secretary was on a 50% contract until May 1998.

Line 9 and 10
- The figures now include further costs associated with meetings which were previously not charged for.

Line 11
- The figure includes the Brochure which was not included in the budget. However, it is less than budgeted due to the December issue newsletter not being paid until 1999.

Line 13 and 14
- The budget for Miscellaneous has been separated into General and Project. The figure in line 14 includes the binders of the Pharmacy-based asthma services, Protocol and guidelines, which were not included in the budget.

Line 15
- The bank fees reflect the real bank fees while the bank charges for transferring money is now reflected in the shortfalls of membership and registration fees actually paid.

In general
The Profit for the year is USD 25,591. However, this is not reflected in the bank balance which shows a reduction in available funds of USD 19,416. The reason for this is that all bank transactions in 1997 were reflected in the bank balance of 1997, although some of them were not reflected in the Profit & Loss of 1997 as they were prepayments for 1998, e.g. membership fees and money for renewal of contracts for the secretariat.
## EuroPharm Forum
### Budget 1999-2000

All figures in US $

<table>
<thead>
<tr>
<th></th>
<th>1999 from Nov.98</th>
<th>1999 (updated Sep.99)</th>
<th>2000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Income</td>
<td>Expenses</td>
<td>Income</td>
</tr>
<tr>
<td>WHO contribution</td>
<td>12,500</td>
<td></td>
<td>127,550</td>
</tr>
<tr>
<td>Membership fees/one-off payment</td>
<td>130,200</td>
<td></td>
<td>126,400</td>
</tr>
<tr>
<td>Support - general (from external funds)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support - projects (from external funds)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secretariat administration</td>
<td>34,500</td>
<td></td>
<td>34,500</td>
</tr>
<tr>
<td>Project coordination/technical assistance</td>
<td>55,700</td>
<td></td>
<td>52,000</td>
</tr>
<tr>
<td>Meetings inc. travel - general</td>
<td>5,000</td>
<td></td>
<td>5,000</td>
</tr>
<tr>
<td>Meetings inc. travel - projects</td>
<td>5,000</td>
<td></td>
<td>3,650</td>
</tr>
<tr>
<td>Annual meeting</td>
<td>10,000</td>
<td></td>
<td>10,000</td>
</tr>
<tr>
<td>Newsletter/publications</td>
<td>4,100</td>
<td></td>
<td>5,800</td>
</tr>
<tr>
<td>WHO Administration cost</td>
<td>15,093</td>
<td></td>
<td>15,000</td>
</tr>
<tr>
<td>Miscellaneous - general</td>
<td>2,000</td>
<td></td>
<td>2,000</td>
</tr>
<tr>
<td>Miscellaneous - project</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>142,700</td>
<td>131,393</td>
<td>127,550</td>
</tr>
<tr>
<td><strong>Loss/Profit</strong></td>
<td>11,307</td>
<td></td>
<td>-400</td>
</tr>
<tr>
<td><strong>Balance</strong></td>
<td>142,700</td>
<td>142,700</td>
<td>127,550</td>
</tr>
</tbody>
</table>

---

Budget 1999-2000 (Annex 4)
Explanatory notes
Budget 1999

The accepted budget of 1999 has been revised in September to more accurately show the actual income and expenses to date. The changes are explained in the notes below:

Line 1:
- The WHO contribution of USD 12,500 has been transferred to Profit & Loss 1998 as the total of USD 25,000 for the biennium 1998-99 was paid and used in 1998.

Line 10:
- The figure has been increased with publications.

Explanatory notes
Budget 2000

Line 1
- The WHO contribution (not yet granted) will, if received, cover the biennium 2000-2001

Line 3
- External funds for twinning programmes with a total amount of USD 30,000 has been granted

Line 5 and 6
- Step increase of salaries included

Line 7
- Increased with activities related to twinning programmes

Line 10
- Production of posters presenting EuroPharm activities is included.

Line 11
- Extra administration costs due to external funds

Line 13
- Includes production of project protocols
The Past
First version of campaign proposal in 1993
Satellite Symposium in Malta 1994
Project implementation in different countries
Satellite Symposium in Hilleroed in 1998: campaign initiatives
First draft on the new version of the campaign proposal 1999.

This Year
We updated the Campaign proposal from 1993.
We finely defined the three levels:
**Level 1**: Active involvement of pharmacists in daily counselling thanks to these 5 questions (Changing the counselling manner)
**Level 2**: Active creating questions through campaigns to the public and giving the information for each new drug delivered.
(Creating a movement in the public to ask for advice before taking medicines)
**Level 3**: Active follow up and correction of drug usage thanks to patient information
(Through counselling, managing the correct usage of medicines (pharmaceutical care)

These three levels will be developed more profoundly in the new protocol and guidelines.
The next updated form (**first new draft**) will be ready on 12 November (levels developed - Evaluation - background)
These guidelines will be presented during the annual meeting and will be sent in the middle of November to the task force members for review and comments. First comments will be discussed with the QAM-task force members in Lisbon.
The evaluation part has to be discussed with the **WHO-QC department** in the next months and is for the moment not added to the manual.
We will have the possibility to create a Steering Committee with ‘experts’ in order to have the material, in particular the evaluation form, reviewed by experts.
Proposal to send a letter to the PCNE and to some experts in Universities to ask for help.

We will ask the task force members for the evolution of there QAM-projects.
All these actions will be reported in the annexes of the new protocol and guidelines.

The Future

Objective: Annual meeting 2000 to present the final draft of the new version of QAM with the new levels and evaluation.
Planning of a new pilot project in different countries together.
Try to get more countries involved in the implementation of this project.
EuroPharm Forum

Asthma Services, Nov. 99

Task force manager: Dr D. Tromp, The Netherlands

The project aims to support pharmacists in dealing with asthma patients in everyday practice at the pharmacy and the task force was established in 1996. The Pharmacy-based Asthma services, Protocol and Guidelines was adopted by the Forum in 1997 and is now available as an official WHO document. The main focus of the Protocol is to provide a systematic and structured approach to pharmacy-based asthma services, including documentation of the pharmacy services, their outcomes and implementation strategies. Furthermore, the purpose is to provide member associations with a tool for national implementation of pharmacy-based asthma services within the framework of Good Pharmacy Practice (GPP).

During a Training Seminar in 1998, a strategy for the implementation of the project was discussed. However, as practice varies from country to country, it was decided that the strategy should build on experiences from those countries implementing the services. Since then the task force manager has tried to find a feasible structure to control and check the country activities. The Quality Model of Donabedian, upon which GPP is based, seems to be useful to divide activities, outcomes and structures at various levels and can also be used for the activities within the asthma project. Furthermore, a database can be created from this model.

A questionnaire, based on this model, was recently sent out to task force members to analyse the situation and the results of this survey will be presented at the Symposium in Lisbon.

The task force has organized a satellite symposium on Asthma Services in European Pharmacies in Lisbon on 13 November 1999. The objectives of the Symposium are to exchange information and share experiences and to present and compare the first results of the interventions in pharmacies. Participants will mainly be task force members and representatives from other organisations.

A specific asthma project newsletter, including information and the provisional programme of the Asthma symposium, has recently been sent out by the task force manager.

**Number of countries participating: 11**

Belgium, Denmark, Finland, France, Germany, Ireland, Malta, The Netherlands, Portugal, Turkey, United Kingdom
CINDI

Countrywide Integrated Noncommunicable Disease Intervention

Pharmacy-based hypertension management programme

Task Force Manager

Annual Report

November 1998 - November 1999

1. Approval of Protocol and Guidelines
   The final draft of both the protocol and guidelines has been presented and approved in the 7th Annual Meeting of EuroPharm Forum, in November 1998, in Copenhagen. This document was also approved at the WHO CINDI Directors' Meeting with some minor corrections that were later on included.
   The guidelines outline the various ways in which pharmacists can provide a hypertension management service at three different levels of intervention: prevention of high blood pressure, detection and management of hypertensive patients under treatment.
   The protocol corresponds to the model description and incorporates the guidelines to be used at the pharmacy as an annex.

2. Training Seminar in May 1999
   Although the WHO CINDI and the Forum initially planned a pilot study, in order to test the feasibility of the model and materials, this was not possible due to the lack of funds.

   Despite this, we were aware that some of our members wished to have some assistance in programme implementation strategies. Therefore, it was decided to run a Training Seminar, focusing on implementation strategies and evaluation procedures, in order to keep up the motivation and interest demonstrated by various countries in such event.

   This Seminar took place in Lyngby, near Copenhagen, in May 1999, with the presence of two WHO CINDI representatives: WHO Regional Advisor for Chronic Disease Prevention Unit and WHO CINDI Programme Director for Spain.

   Participants had the opportunity, at the end of the Seminar, to present pharmacy-based hypertension management current activities in the respective countries and to share different experiences. A summary of these presentations was published in a special Newsletter of EuroPharm Forum sent to all member associations' participants in August 1999.

3. Pilot study
   In September 1999, the WHO CINDI team and the EuroPharm Forum have agreed to run a pilot study, in 5 or 6 countries, which purpose would be to test the feasibility of the Protocol and Guidelines, in what concerns the model itself, the implementation strategy and evaluation procedures. Thus, the draft will now be considered as a first version for a feasibility study.
   The countries to be included in the pilot study will have to be selected and identified by mutual agreement between the EuroPharm Forum and the WHO CINDI network. Which is exactly the stage we have reached so far.

   Suzete Costa
   CINDI Task Force Manager
Pharmacist in Diabetes Care

Report from Task Force Manager
1998/1999

M. Augusta Soares

The evolution of the PharmaDiaβ Programme during the last year.

1. 5th meeting of St. Vincent Declaration Action Programme – Istanbul October 1999

By the 10th St. Vincent Declaration (SVD) anniversary, it was held in Istanbul, the 5th meeting of St. Vincent Declaration Action Programme. During this meeting, the pharmacists were responsible for:

a) The pharmacists working group workshop, in which was discussed the evaluation form for the pharmacist intervention on diabetes care.

b) In the poster section, 7 posters from the pharmacists of Croatia, France, Germany, Portugal and United Kingdom were presented.

c) The pharmacists were represented in the Cluster Group of Expanding diabetes team, together with the other working groups. Here, the Recommendations from the workshop, were presented, as follows:

- To focus the pharmacist intervention on:
  - Drug related problems;
  - Patient information and education;
  - Diabetes early detection.

- To finalise the evaluation form – Basic Information Sheet for Pharmacists (BISP), to be used at local, national and European levels, including Well-being score, from the 5 items WHO Scale.

- To go on working as a team with other health professionals.

- To keep diabetes knowledge updated.

- To adapt the pharmacist guidelines on Diabetes Care, according to each country possibilities.

2. Home Page

The PharmaDiaβ Home Page was prepared, to be included in the EuroPharm Forum Home Page.

3. Basic Information Sheet for Pharmacists (BISP)

Based on the guidelines, one version of the BISP was prepared, which was discussed during SVD meeting and that has to suffer some changes.

4. SVD Newsletter

In the last SVD Newsletter, the summary of the Status of PharmaDiaβ Programme was published.
5. Well Being Scale
We sent all the EuroPharm Forum Pharmacist Associations, the rules to translate into each language the Well Being Scale proposed by WHO, to be used in all the Programmes.


a) Through Pharmacy Associations, 18 countries are interested in PharmaDiaβ Programme involvement: Belgium, Croatia, Finland, France, Germany, Ireland, Latvia, Luxembourg, Malta, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom.

b) There is one Pharmacist co-ordinator in 11 of the countries.

c) Ten of the countries are working, based on the proposed PharmaDiaβ Programme guidelines.

d) There are training courses for pharmacists running in 10 of the countries and, in 13 of them, there is some education material for pharmacists.

e) The pharmacists are involved in other activities, in what concerns of diabetes care, in ten of the countries.

f) Information to the Government and health professionals about this programme was done by 10 of the countries.

g) There are Patient’ leaflets in 12 of the countries. Some of them prepared more than 1 themes:

   Ex.: 2: Croatia, the Netherlands, Turkey
         8: Portugal


h) The pharmacists are allowed to evaluate the patient glycaemia in: Belgium, Finland, France, Germany, Ireland, Malta, Norway, Portugal, Slovenia, Spain

i) The pharmacists are allowed to evaluate the patient blood pressure, in: Belgium, Finland, France, Germany, Ireland, Luxembourg, Malta, Norway, Portugal, Spain, UK.
Education and publications

1. The basic document of the task force "The role of the pharmacist in smoking cessation" was published as Booklet No 12 in the Smoke-free Europe series just before the last annual meeting.
2. During the annual meeting a session “Third action plan for a Tobacco-Free Europe” was held. During this session the WHO-project was presented as well as our own task force and the role of pharmacists and their national organisations in non-smoking work.
3. Posters presenting the task force and its work have been presented in the 2nd European Conference on Tobacco or Health in Las Palmas de Gran Canaria and in the FIP-congress in Barcelona.

Research work

1. A research project concerning the effectiveness of local co-operation in primary health care concerning smoking cessation has been started in Finland. The aim of this project is to find out models on how to develop effective non-smoking networks.
2. A survey concerning the smoking status of pharmacists and their attitudes towards non-smoking work has been planned. For this survey financial support has been applied from EU-fonds via European Network on Smoking Prevention.

Contact-keeping

1. Task force manager has sent six letters to task force members. In these letters we have discussed latest progress in the survey and explained the methodology and informed about news in the task force.
2. Several letters have been sent to the national member organisations in EU-countries concerning the survey.
3. Task force members and national organisations in EU-countries have responded well and there has been good discussion mainly about the survey.
4. A meeting for those countries willing to participate to the survey was organised in Barcelona during the FIP-congress.

WHO European Partnership Project on Tobacco Dependence

1. Professional secretary Ida Gustafsen is a member of the Project Group of the Partnership Project.
2. Task force manager Eeva Teräsalmi attended the conference on the Regulation of Tobacco Products 18th October in Helsinki and will attend the meeting on Evidence Based Treatment on 24th November in London.

Co-operation with FIP

1. A proposal for a half day seminar during the FIP-congress in Vienna 2000 has been planned.
List of Participants

**Albania**
Dr Skender **Durresi**  
President  
Albanian Pharmaceutical Association  
Fakulteti Shkencave Natyrore  
Buleyard “Deshmoret E Kombit”  
Tirana  
Phone: +355 42 39894  
Fax: +355 42 2492  
E-mail: durresi@fshn.tirana.al

**Austria**
Mr Leopold **Schmudermaier**  
Oesterreichische Apothekerammer  
Spitalgasse 31  
A-1091 Wien  
Phone: +43 1 404 14108  
Fax: +43 1 408 8440

Dr Herbert **Cabana**  
Oesterreichische Apothekerammer  
Spitalgasse 31  
A-1091 Wien  
Phone: +43 1 404 14108  
Fax: +43 1 408 8440  
E-mail: cabana@apotheker.or.at

Ms Karin **Oberdorfer**  
Oesterreichische Apothekerammer  
Spitalgasse 31  
A-1091 Wien  
Phone: +43 1 404 14198  
Fax: +43 1 408 8440  
E-mail: oberdorfer@potheker.or.at

**Belgium**
Mr André **Masy**  
Association Pharmaceutique Belge  
Rue Archimede 11  
B-1000 Brussels  
Phone: +32 2 285 4222  
Fax: +32 2 285 4275

Mr Dirk **Broeckx**  
Association Pharmaceutique Belge  
Rue Archimede 11  
B-1000 Brussels  
Phone: +32 2 285 4204  
Fax: +32 2 285 4285  
E-mail: broeckx.dirk@mail.apb.be
ANNEX 11

Croatia
Ms Maja Jaksevac-Miksa  
Croatian Pharmaceutical Society  
Masarykova 2  
11000 Zagreb

Czech Republic
Ms Marie Zajicova  
The Czech Chamber of Pharmacists  
Poliklinika Budejovicka  
Antala Staska 80  
140 46 Praha 4

Denmark
Mr Steffen Zederkof  
Danish Pharmaceutical Association  
Postboks 2181  
Bredgade 54  
1017 Copenhagen

Ms Anna Marie Christiansen  
Association of Danish Pharmacists  
Rygård's Alle 1  
2900 Hellerup

Ms Hanne Herborg  
Danish College of Pharmacy Practice  
Milnersvej 42  
3400 Hillerød, Denmark

Estonia
Mr Toivo Soosaar  
Chairman  
Society of Estonian Pharmacy  
Paernu Mnt. 102  
EE-0013 Tallin

Finland
Mr Reijo Purasmaa  
The Association of Finnish Pharmacies  
Pieni Roobertinkatu 14 C  
SF-00120 Helsinki

France
Ms Annick Dulion  
Conseil national de l’Ordre des Pharm.  
89 rue de la Faisanderie  
75116 Paris

Participants 8th Annual Meeting 1999 (Annex 11)
France cont’d…
Ms Florence Guillier
Conseil national de l’Ordre des Pharm.
89 rue de la Faisanderie
75116 Paris

Mr Henri Lepage
Conseil national de l’Ordre des Pharm.
4 rue de Patay
45000 Orléans

Ms Josette Dubray
Conseil national de l’Ordre des Pharm.
4 rue de Patay
45000 Orléans

Mr Philippe Liebermann
Fédération des Syndicats Pharmaceutiques de France
15 rue du Rahes auhauses
67100 Strasbourg

Germany
Mr Hans-Günter Friese
ABDA
Carl Mannich St. 26
65760 Eschborn

Mr Frank Verheyen
ABDA
Carl Mannich St. 26
65760 Eschborn

Dr Susanne Hof
ABDA Brussels
1 Rue Newton
1000 Brussels, Belgium

Hungary
Dr Antal Samu
Hungarian Private Pharmacists Assoc.
Zrinyi u. 3
1051 Budapest

Iceland
Ms Gudrun Kjartansdottir
President
Pharmaceutical Society of Iceland
v/Neströð - Box 252
172 Seltjarnarnes
ANNEX 11

Ireland

Mr Brendan Quinn
Irish Pharmaceutical Association
Butterfield House
Butterfield Avenue
Rathfarnham
Dublin 14

Mr Diarmund O'Donovan
Irish Pharmaceutical Association
Butterfield House
Butterfield Avenue
Rathfarnham
Dublin 14

Dr Paul Grassby
ICCPE
Unit 2, 19-20 York Road
Dun Laoghaire
Dublin

Israel

Mr Avi Raz
The Pharmaceutical Association of Israel
12 Levontin St.
Tel-Aviv 65112

Latvia

Ms Sandra Berzina
Vice-President
Pharmacists Society of Latvia
Ernestines Str. 33
1046 Riga

Lithuania

Mr Eduardas Tarasevicius
Lithuanian Pharmaceutical Association
Traku 14
2025 Vilnius

Mr Merimantas Steikunas
Lithuanian Pharmaceutical Association
Traku 14
2025 Vilnius
Luxembourg
Mr Jean Claude Ast
Union Nationale des Pharmaciens Luxembourgeois
12 Ceinture des Rosiers
2446 Howald
Phone: +352 29 6333
Fax: +352 29 6332
E-mail: unaphalu@pt.lu

Malta
Ms Mary Ann Sant Fournier
President
Malta Chamber of Pharmacists
Alamein Road
Pembroke
Phone: +356 378 851
Fax: +356 376 540
E-mail: mfpb@maltanet.net

Moldova, Republic of
Prof. Vasile Procopishin
President
Association of Pharmacists of Moldova
Grenoble str. 149 a
Chisinau
Phone: +373 224 2344
Fax: +373 272 7822
E-mail: +373 272 7758

Netherlands
Mr Loek Arts
KNMP
Alexanderstraat 11
2500 GL The Hague
Phone: +31 653 79 8342
Fax: +31 346 55 3839
E-mail: pelzer@wxs.nl

Norway
Mr Martin Bjerke
The Norwegian Assoc. of Pharmacists
Tollbugaten 35
0157 Oslo
Phone: +47 2102 3353
Fax: +47 2102 3350
E-mail: martin.bjerke@farmaceutur.no

Poland
Dr Jerzy Lazowski
Polish Pharmaceutical Chamber
Naczelna Rada Aptekarska
Długa 16F
00-238 Warsaw
Phone: +48 22 635 0670
Fax: +48 22 635 0670
ANNEX 11

Poland cont'd…
Mr Michal Umbreit
Polish Pharmaceutical Chamber
Naczelna Rada Aptekarska
Dluga 16F
00-238 Warsaw
Phone: +48 22 831 0243
Fax: +48 22 831 0243
E.mail: unbreit@main.amu.edu.pl

Portugal
Mr Joao Silveira
President
Ordem dos Farmaceuticos
Rua da Sociedade Farmaceutica, 18
1150 Lisbon
Phone: +351 21 319 1370
Fax: +351 21 319 1399
E-mail: dirnacional@ordemfarmaceuticos.pt

Ms Ivana Silva
Ordem dos Farmaceuticos
Rua da Sociedade Farmaceutica, 18
1150 Lisbon
Phone: +351 21 319 1370
Fax: +351 21 319 1399
E-Mail: ivanasilva@ordemfarmaceuticos.pt

Ms Maria Augusta Soares
Associaçao Nacional das Farmacias
Rua Marechal Saldanha 1
1200 Lisbon
Phone: +351 21 340 0600
Fax: +351 21 347 8939
E-mail: anf@anf.pt

Ms Suzete Costa
Associaçao Nacional das Farmacias
Rua Marechal Saldanha 1
1200 Lisbon
Phone: +351 21 340 0600
Fax: +351 21 347 8939
E-mail: suzete.costa@anf.pt

Romania
Mr Robert Sandulescu
College of Pharmacists of Romania
Splainl Independentei, no. 102A
70138 Bucharest
Phone: +40 94 63 1137
Fax: +40 1 698 24 040

Mr Horia Bucur
College of Pharmacists of Romania
Splainl Independentei, no. 102A
70138 Bucharest
Phone: +40 94 63 1137
Fax: +40 1 698 24 040

Russian Federation
Mr Alexander Arzamastcev
Pharmaceutical Association of Russia
7/5 Dmitrovka St.
GSP Moscow 101 43
Phone: +7 095 290 6926
Fax: +7 095 292 9889
Slovenia
Ms Darja Frankic
Slovenian Chamber of Pharmacy
Ulica stare pravde 11
1000 Ljubljana

Phone: +386 6113 24003
Fax: +386 6113 18168

Spain
Ms Blanca Gutiérrez-Colomer
Spanish Council of Pharmacists
Villanueva 11
28001 Madrid

Phone: +34 91 431 2560
Fax: +34 91 576 3905
E-mail: congral@recol.es

Sweden
Mr Bo Gunnarsson
Swedish Pharmaceutical Society
Box 1136
11181 Stockholm

Phone: +46 8 723 5000
Fax: +46 8 20 5511
E-mail: bo.gunnarsson@apoteket.se

United Kingdom
Mr Hemant Patel
President
Royal Pharmaceutical Society of Great Britain
1 Lambeth High Street
London SE1 7JN

Phone: +44 171 735 9141
Fax: +44 171 582 3401
E-mail: secreg@compuserve.com

Mr Sultan Dajani
Royal Pharmaceutical Society of Great Britain
1 Lambeth High Street
London SE1 7JN

Phone: +44 171 735 9141
Fax: +44 171 582 3401
E-mail: sid2708@aol.com

Ms Christine Gray
Royal Pharmaceutical Society of Great Britain
1 Lambeth High Street
London SE1 7JN

Phone: +44 171 735 9141
Fax: +44 171 582 3401
E-mail: cgray@rpsgb.org.uk

Mr Wally Dove
The National Pharmaceutical Association
Segensworth House
Mill Lane
Titchfield, Hants PO15 5DU

Phone: +44 132 984 7047
Fax: +44 132 984 7047

Mrs Colette McCready
The National Pharmaceutical Association
Mallinson House
38-42 St Peter's Street
St Albans, Herts AL1 3NP

Phone: +44 172 783 2161
Fax: +44 172 784 0858
E-mail: c.mccready@npa.co.uk
ANNEX 11

Observer Organizations

**EPSA**
Mr Arthur Franken  
President,  
European Pharmaceutical Students Assoc.  
Pieterskerkchoorsteeg 19  
2311 TR Leiden, The Netherlands  

Ms Sarah Caruana  
Vice-President  
European Pharmaceutical Students Assoc.  
Malta.

**EIPG**
Ms Maria Terese Cosme  
European Industrial Pharmacists Group  
Ordem dos Farmaceuticos  
Rua da Sociedade Farmaceutica, 18  
1150 Lisbon, Portugal

**PCNE**
Prof. Foppe van Mil  
Pharmaceutical Care Network Europe  
Margrietlaan 1  
9471 CT Zuidlaren, The Netherlands

**PGEU**
Ms Lisette Tiddens-Engwirda  
Pharmaceutical Group of EU  
Square Ambiorix 13  
1000 Brussels, Belgium

Guests

Mr Joep Winters  
Singelapotheek  
Binnensingel 10  
7411 PM Deventer, The Netherlands  

Mr John Ferguson  
Royal Pharmaceutical Society of Great Britain  
1 Lambeth High Street  
London SE1 7JN, United Kingdom
World Health Organization
Regional Office Europe

Dr J. Asvall
Regional Director

Ms Ida Gustafsen
Professional Secretary
EuroPharm Forum
Programme for Pharmaceuticals

Ms Julia Trangeled
Secretary
EuroPharm Forum
Programme for Pharmaceuticals

Phone: +45 3917 1515
Fax: +45 3917 1855
e-mail: igu@who.dk

Phone: +45 3917 1330
Fax: +45 3917 1855
e-mail: jtr@who.dk